Literature DB >> 16469823

The French National Mesothelioma Surveillance Program.

M Goldberg1, E Imbernon, P Rolland, A Gilg Soit Ilg, M Savès, A de Quillacq, C Frenay, S Chamming's, P Arveux, C Boutin, G Launoy, J C Pairon, P Astoul, F Galateau-Sallé, P Brochard.   

Abstract

OBJECTIVES: The French National Mesothelioma Surveillance Program (NMSP) was established in 1998 by the National Institute for Health Surveillance (InVS). Its objectives are to estimate the trends in mesothelioma incidence and the proportion attributable to occupational asbestos exposure, to help improve its pathology diagnosis, to assess its compensation as an occupational disease, and to contribute to research.
METHODS: The NMSP records incident pleural tumours in 21 French districts that cover a population of approximately 16 million people (a quarter of the French population). A standardised procedure of pathological and clinical diagnosis ascertainment is used. Lifetime exposure to asbestos and to other factors (man made mineral fibres, ionising radiation, SV40 virus) is reconstructed, and a case-control study was also conducted. The proportion of mesothelioma compensated as an occupational disease was assessed.
RESULTS: Depending on the hypothesis, the estimated number of incident cases in 1998 ranged from 660 to 761 (women: 127 to 146; men: 533 to 615). Among men, the industries with the highest risks of mesothelioma are construction and ship repair, asbestos industry, and manufacture of metal construction materials; the occupations at highest risk are plumbers, pipe-fitters, and sheet-metal workers. The attributable risk fraction for occupational asbestos exposure in men was 83.2% (95% CI 76.8 to 89.6). The initial pathologist's diagnosis was confirmed in 67% of cases, ruled out in 13%, and left uncertain in the others; for half of the latter, the clinical findings supported a mesothelioma diagnosis. In all, 62% applied for designation of an occupational disease, and 91% of these were receiving workers' compensation.
CONCLUSIONS: The NMSP is a large scale epidemiological surveillance system with several original aspects, providing important information to improve the knowledge of malignant pleural mesothelioma, such as monitoring the evolution of its incidence, of high risk occupations and economic sectors, and improving pathology techniques.

Entities:  

Mesh:

Year:  2006        PMID: 16469823      PMCID: PMC2078115          DOI: 10.1136/oem.2005.023200

Source DB:  PubMed          Journal:  Occup Environ Med        ISSN: 1351-0711            Impact factor:   4.402


  15 in total

1.  Cancer incidence and mortality in France over the period 1978-2000.

Authors:  L Remontet; J Estève; A-M Bouvier; P Grosclaude; G Launoy; F Menegoz; C Exbrayat; B Tretare; P-M Carli; A-V Guizard; X Troussard; P Bercelli; M Colonna; J-M Halna; G Hedelin; J Macé-Lesec'h; J Peng; A Buemi; M Velten; E Jougla; P Arveux; L Le Bodic; E Michel; M Sauvage; C Schvartz; J Faivre
Journal:  Rev Epidemiol Sante Publique       Date:  2003-02       Impact factor: 1.019

2.  [Regional differences in the compensation of pleural mesothelioma as occupational disease in France (1986-1993)].

Authors:  M Goldberg; S Goldberg; D Luce
Journal:  Rev Epidemiol Sante Publique       Date:  1999-10       Impact factor: 1.019

3.  Malignant mesothelioma in Australia, 1945-2000.

Authors:  James Leigh; Patricia Davidson; Leigh Hendrie; Dale Berry
Journal:  Am J Ind Med       Date:  2002-03       Impact factor: 2.214

4.  Well-differentiated papillary mesothelioma of the pleura: a series of 24 cases.

Authors:  Françoise Galateau-Sallé; Jean Michel Vignaud; Louise Burke; Allen Gibbs; Elisabeth Brambilla; Richard Attanoos; Marcel Goldberg; Guy Launoy
Journal:  Am J Surg Pathol       Date:  2004-04       Impact factor: 6.394

5.  Pleural mesothelioma incidence in Europe: evidence of some deceleration in the increasing trends.

Authors:  Fabio Montanaro; Freddie Bray; Valerio Gennaro; Enzo Merler; Jerzy E Tyczynski; Donald Maxwell Parkin; Marija Strnad; Marie Jechov'a; Hans H Storm; Tiiu Aareleid; Timo Hakulinen; Michel Velten; Hacina Lef'evre; Arlette Danzon; Antoine Buemi; Jean-Pierre Daur'es; François Ménégoz; Nicole Raverdy; Martine Sauvage; Hartwig Ziegler; Harry Comber; Eugenio Paci; Marina Vercelli; Vincenzo De Lisi; Rosario Tumino; Roberto Zanetti; Franco Berrino; Giorgio Stanta; Frøydis Langmark; Jadwiga Rachtan; Ryszard Mezyk; Jerzy Blaszczyk; Plesko Ivan; Maja Primic-Zakelj; Alvaro Cañada Martínez; Isabel Izarzugaza; Joan Borràs; Carmen Martínez Garcia; Isabel Garau; Navarro Carmen Sánchez; Ardanaz Aicua; Lotti Barlow; Joachim Torhorst; Christine Bouchardy; Fabio Levi; Thomas Fisch; Nicole Probst; Otto Visser; Mike Quinn; Anna Gavin; David Brewster; Marica Mikov
Journal:  Cancer Causes Control       Date:  2003-10       Impact factor: 2.506

6.  Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003.

Authors:  Bertram Price; Adam Ware
Journal:  Am J Epidemiol       Date:  2004-01-15       Impact factor: 4.897

7.  Incidence trends of mesothelioma in Norway, 1965-1999.

Authors:  Bente Ulvestad; Kristina Kjaerheim; Bjørn Møller; Aage Andersen
Journal:  Int J Cancer       Date:  2003-10-20       Impact factor: 7.396

8.  Estimation of the past and future burden of mortality from mesothelioma in France.

Authors:  A G Ilg; J Bignon; A J Valleron
Journal:  Occup Environ Med       Date:  1998-11       Impact factor: 4.402

9.  Malignant mesothelioma in North America.

Authors:  A D McDonald; J C McDonald
Journal:  Cancer       Date:  1980-10-01       Impact factor: 6.860

10.  Malignant mesothelioma in Italy, 1997.

Authors:  Massimo Nesti; Alessandro Marinaccio; Elisabetta Chellini
Journal:  Am J Ind Med       Date:  2004-01       Impact factor: 2.214

View more
  51 in total

Review 1.  What's the place of immunotherapy in malignant mesothelioma treatments?

Authors:  Marc Grégoire
Journal:  Cell Adh Migr       Date:  2010-01-30       Impact factor: 3.405

2.  Syntenic relationships between genomic profiles of fiber-induced murine and human malignant mesothelioma.

Authors:  Didier Jean; Emilie Thomas; Elodie Manié; Annie Renier; Aurélien de Reynies; Céline Lecomte; Pascal Andujar; Jocelyne Fleury-Feith; Françoise Galateau-Sallé; Marco Giovannini; Jessica Zucman-Rossi; Marc-Henri Stern; Marie-Claude Jaurand
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 3.  Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.

Authors:  Zhongjian Chen; Giovanni Gaudino; Harvey I Pass; Michele Carbone; Haining Yang
Journal:  Transl Lung Cancer Res       Date:  2017-06

4.  [Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma].

Authors:  A Scherpereel; P Astoul; P Baas; T Berghmans; H Clayson; P de Vuyst; H Dienemann; F Galateau-Salle; C Hennequin; G Hillerdal; C Le Pe'choux; L Mutti; J-C Pairon; R Stahel; P van Houtte; J van Meerbeeck; D Waller; W Weder
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2010-10

5.  BTS statement on malignant mesothelioma in the UK, 2007.

Authors: 
Journal:  Thorax       Date:  2007-11       Impact factor: 9.139

6.  Canadian cancer statistics at a glance: mesothelioma.

Authors:  Loraine D Marrett; Larry F Ellison; Dagny Dryer
Journal:  CMAJ       Date:  2008-03-11       Impact factor: 8.262

7.  Malignant pleural mesothelioma treated in Clinic for Pulmonary Diseases and Tuberculosis "Podhrastovi" in ten-year period (from 1998 to 2007).

Authors:  Vesna Cukić; Aida Ustamujić; Vladimir Lovre; Hasan Zutić; Sadika Genjac; Mina Masić-Zecević
Journal:  Bosn J Basic Med Sci       Date:  2008-11       Impact factor: 3.363

Review 8.  Malignant mesothelioma: facts, myths, and hypotheses.

Authors:  Michele Carbone; Bevan H Ly; Ronald F Dodson; Ian Pagano; Paul T Morris; Umran A Dogan; Adi F Gazdar; Harvey I Pass; Haining Yang
Journal:  J Cell Physiol       Date:  2012-01       Impact factor: 6.384

Review 9.  Mesothelioma: recent highlights.

Authors:  Michele Carbone; Haining Yang
Journal:  Ann Transl Med       Date:  2017-06

Review 10.  Environmental asbestos exposure and risk of mesothelioma.

Authors:  Curtis W Noonan
Journal:  Ann Transl Med       Date:  2017-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.